Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

raltitrexed disodium

The disodium salt form of raltitrexed, a quinazoline folate analogue, with potential antineoplastic activity. Upon administration of raltitrexed, this agent is taken up by cells via the reduced folate carrier, undergoes intracellular polyglutamation, and blocks the folate-binding site of thymidylate synthase (TS). This inhibits the conversion of deoxyuridine monophosphate (dUMP) into deoxythymidine monophosphate (dTMP) and thus increases dUMP levels and decreases the amount of deoxythymidine triphosphate (dTTP) available for DNA synthesis. This prevents DNA replication and repair, and leads to DNA fragmentation and cell death, and results in reduced tumor cell 'proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Foreign brand name:Tomudex
Chemical structure:L-glutamic acid, N-((5-(((3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl)-, disodium salt
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search